JETi Peripheral Thrombectomy System | Abbott
CARDIOVASCULAR
hamburger
JETi™

The JETi™ Thrombectomy System is designed to treat both peripheral arterial thrombosis and peripheral venous thrombosis.1

The JETi™ thrombectomy device leverages cutting-edge technology to treat both peripheral arterial and venous thrombus with a novel hydrodynamic system.1 Utilizing a uniquely positioned high-pressure saline jet, JETi is able to fragment and lubricate clot safely within the catheter lumen to help avoid clogging1 and potential patient exposure to hemolytic compounds.2,4 With HyperPulse™ Fluid Delivery, JETi can also sub selectively infuse/deliver diagnostics or therapeutics intra-procedurally.1

The JETi™ Thrombectomy System Macerates and Aspirates Clot for Single Session Efficiency and Outcomes1,2

Built for Efficiency

  • Novel hydrodynamic system design macerates clot within the catheter lumen to help avoid clogging1
  • High single-session treatment success rate4 to help reduce costly ICU length of stay5

Minimized Complications

  • Minimized risk of emoblization4,7 and hemolysis4 due to unique mechanism of action
  • Low profile 6Fr and 8Fr catheters6 to help avoid large-bore access site complications8

All-In-One Versatility

  • Ability to infuse thrombus with therapeutic agents utilizing the Hyper Pulse™ Fluid Delivery1
  • Designed to treat both peripheral arterial and venous thrombus1

References

  1. JETi™ Thrombectomy System Instructions for Use (IFU). Refer to IFU for additional information.
  2. Razavi et al. JVIR. 2021.
  3. Rohr, A et al. JVIR. 2019 Oct;30(10):1682-1685.
  4. Cournoyer-Rodrigue et al. JVIR. 2020 Mar;31(3):444-453.
  5. Khalsa, B., et al. JVIR, 2020.
  6. Data on file at Abbott.
  7. Moser, K et al. JAMA. 1994 Jan;271(3):223-225
  8. Redfors, B., et al. JAMA Cardiology. 2017.

MAT-2116428 v1.0

Important Safety Information
Request a Demo

IMPORTANT SAFETY INFORMATION

rx-only-logo  JETi™ All-In-One Peripheral Thrombectomy System


Indications

The JETi™ AIO Peripheral Thrombectomy System is intended to remove/aspirate fluid and break-up soft emboli and thrombus from the peripheral vasculature and to sub selectively infuse/deliver diagnostics or therapeutics with or without vessel occlusion.
 

Contraindications

The JETi™ AIO Peripheral Thrombectomy System is contraindicated for use in:

  • Vessels smaller than 4 mm (0.16”)
  • Coronary, pulmonary, and neurovasculature


Warnings

The JETi™ Peripheral Catheter, JETi™ AIO Suction Tubing, and JETi™ Pump Set contents are supplied sterile using EO. Do not use if the expiration date has passed or the sterile barrier is damaged.

  • The JETi™ Peripheral Catheter, JETi™ AIO Suction Tubing, JETi™ AIO Non-Sterile Kit, and JETi™ Pump Set contents are for single patient use only. Dispose after use. Do not reuse, reprocess, modify, or resterilize. Reuse, reprocessing, modification, or resterilization may compromise the structural integrity of the device and/or lead to device failure which, may result in patient injury, illness or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness, or death of the patient.
  • The JETi™ AIO Peripheral Thrombectomy System is not approved for use with defibrillation. In the event shock must be delivered to the patient, remove the catheter and clear all connected system components from the patient before delivering shock.
  • Do not use a catheter that has been kinked or damaged.
  • Do not use a pump set if it does not prime.
  • Only use the JETi™ Peripheral Catheter and JETi™ AIO Suction Tubing with the JETi™ AIO Peripheral SDU.
  • Do not mix contrast media in the saline bag.
  • When the catheter is exposed to the arterial system, it should be manipulated while under high-quality fluoroscopic observation.
  • In the event that the catheter becomes blocked or clogged with thrombus, remove and replace the device with a new device.
  • Do not use if package is opened or damaged.
  • To avoid risk of electric shock, the SDU must only be connected to mains power with a protective earth.
  • The power socket-outlet must be located near the device and must be easily accessible.
  • Do not modify or alter the device.
  • Do not step or stand on the base of the device.
  • Do not push or lean against the IV pole.


Precautions

Physicians must read and understand the Instructions for Use (IFU) prior to using the device. The device must be used by physicians skilled in percutaneous, intravascular techniques in a fully equipped catheterization laboratory.
 

Potential Adverse Effects

Potential adverse events include, but are not limited to:

  • Acute closure
  • Aneurysm or pseudo aneurysm
  • Allergic reaction to contrast
  • Arrhythmia
  • Death
  • Embolism (air or device)
  • Embolization (thrombotic)
  • Emergency surgery
  • Access site pain, hemorrhage, or hematoma
  • Infection (systemic/sepsis)
  • Local infection (puncture site)
  • Minimal blood loss
  • Vessel dissection, perforation, or other injury
  • Vessel spasm
  • Thrombosis

JETi™ is a trademark of Walk Vascular. Walk Vascular is a subsidiary of the Abbott Group of Companies.
Manufactured by Walk Vascular LLC 17171 Daimler Street, Irvine CA, 92614 USA

MAT-2116195 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.